Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Chinese Journal of Preventive Medicine ; (12): 100-106, 2023.
Article in Chinese | WPRIM | ID: wpr-969850

ABSTRACT

This article reviews the relevant studies on the efficacy and safety of influenza, pneumococcal and COVID-19 vaccination among tumor patients worldwide in recent years. By combing and analyzing the retrieved literature, the results show that influenza and pneumococcal vaccination can significantly reduce the morbidity and hospitalization rate of infectious diseases in tumor patients, reduce the risk of cardiovascular events and death, and significantly improve survival prognosis. COVID-19 vaccination can also protect tumor patients, especially those who have completed full dose vaccination. Authoritative guidelines and consensuses worldwide all recommend that tumor patients receive influenza, pneumococcal and COVID-19 vaccines. We should carry out relevant researches, as well as take effective measures to strengthen patient education, so that tumor patients can fully experience the health protection brought by the vaccine to this specific group.


Subject(s)
Humans , Influenza, Human/prevention & control , COVID-19 Vaccines , COVID-19/prevention & control , Influenza Vaccines/therapeutic use , Vaccination , Pneumococcal Vaccines/therapeutic use , Streptococcus pneumoniae , Neoplasms
2.
Chinese Journal of Epidemiology ; (12): 436-439, 2022.
Article in Chinese | WPRIM | ID: wpr-935408

ABSTRACT

This paper reviews the domestic and foreign studies published in 2020 on the application of influenza vaccine in populations at high risk. The importance of influenza vaccination in population at high risk has been proved by larger sample, multicentre, high-quality evidence-based studies. Influenza vaccination is the most cost-effective measure to prevent influenza. However, the coverage rate of influenza vaccine is very low in China, it is necessary to strengthen the health education to promote influenza vaccination in different populations. It is recommended to give influenza vaccination to the population in whom influenza vaccination has been proven safe and effective before influenza season. Research of the safety, efficiency and cost-effectiveness of influenza vaccine should be accelerated for the populations in whom such data are lacking or insufficient.


Subject(s)
Humans , China , Costs and Cost Analysis , Influenza Vaccines/adverse effects , Influenza, Human/prevention & control , Vaccination
SELECTION OF CITATIONS
SEARCH DETAIL